Amylyx says FDA grants avexitide Breakthrough Therapy, Orphan Drug status for post-bariatric hypoglycemia

• Amylyx plans to submit an FDA New Drug Application for avexitide in post-bariatric hypoglycemia by year-end 2026.
• Phase 3 LUCIDITY met the FDA-agreed primary endpoint, cutting Level 2 and Level 3 hypoglycemic events 55% versus placebo (p=0.000003).
• Avexitide holds FDA Breakthrough Therapy designation, supporting a potential 2027 launch if cleared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.